please read this

[Guest guest]

When I see messages like this, I have to wonder why the person cannot simply

go to the website and unsub in the same manner that they manages to

subscribe in the first place????

Inquiring minds...

Kathy

Please read this

Importance: High

I just received a very angry letter from someone who thinks I was

deliberately not removing her name from the list. I had written about a

week ago telling you all of my computer deleting my " contact list " again and

that my address book might still have you in the wrong place or have

reverted to old information. Apparently she did not receive this email, or

did not read it, so I am sending a reminder now - please DO NOT ASSUME I AM

IGNORING YOU. I am trying my best to overcome whatever it is my computer is

doing.

I realize that this is a pain in the neck for many of you, but you can't

imagine what it is for me - I've spent hours correcting this only to have it

undone. I already work on this issue every day, 10-15 hours a day usually,

and am fixing any problems I am aware of. But I have to be made aware of

them. Please believe me.

Sandy from Alaska

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE

DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

[Guest guest]

Kathy, This person didn't actually subscribe. There is no way to unsubscribe

from my emails other than to contact me.

I have created lists from people emailing me for other reasons, like signing the

letter. Most of them are happy to be in my egroups, but some are not.

Thanks for your sympathetic ear. Sandy

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION

WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

Please read this

Importance: High

I just received a very angry letter from someone who thinks I was

deliberately not removing her name from the list. I had written about a

week ago telling you all of my computer deleting my " contact list " again and

that my address book might still have you in the wrong place or have

reverted to old information. Apparently she did not receive this email, or

did not read it, so I am sending a reminder now - please DO NOT ASSUME I AM

IGNORING YOU. I am trying my best to overcome whatever it is my computer is

doing.

I realize that this is a pain in the neck for many of you, but you can't

imagine what it is for me - I've spent hours correcting this only to have it

undone. I already work on this issue every day, 10-15 hours a day usually,

and am fixing any problems I am aware of. But I have to be made aware of

them. Please believe me.

Sandy from Alaska

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE

DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

[Guest guest]

Thanks, Kathy. Sandy

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION

WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

Please read this

Importance: High

I just received a very angry letter from someone who thinks I was

deliberately not removing her name from the list. I had written about a

week ago telling you all of my computer deleting my " contact list " again

and

that my address book might still have you in the wrong place or have

reverted to old information. Apparently she did not receive this email,

or

did not read it, so I am sending a reminder now - please DO NOT ASSUME I

AM

IGNORING YOU. I am trying my best to overcome whatever it is my

computer is

doing.

I realize that this is a pain in the neck for many of you, but you

can't

imagine what it is for me - I've spent hours correcting this only to

have it

undone. I already work on this issue every day, 10-15 hours a day

usually,

and am fixing any problems I am aware of. But I have to be made aware

of

them. Please believe me.

Sandy from Alaska

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE

CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT

TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE

DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

[Guest guest]

Sandy,

I understand. I just hate it when I see moderators get slammed because

people can't figure out how to go back and unsub from a simple list....and I

have seen it happen on every list I am on.

At any rate...you do a great job...keep up the good work

Kathy

Re: Please read this

Kathy, This person didn't actually subscribe. There is no way to

unsubscribe from my emails other than to contact me.

I have created lists from people emailing me for other reasons, like

signing the letter. Most of them are happy to be in my egroups, but some

are not.

Thanks for your sympathetic ear. Sandy

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE

DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

Please read this

Importance: High

I just received a very angry letter from someone who thinks I was

deliberately not removing her name from the list. I had written about a

week ago telling you all of my computer deleting my " contact list " again

and

that my address book might still have you in the wrong place or have

reverted to old information. Apparently she did not receive this email,

or

did not read it, so I am sending a reminder now - please DO NOT ASSUME I

AM

IGNORING YOU. I am trying my best to overcome whatever it is my

computer is

doing.

I realize that this is a pain in the neck for many of you, but you

can't

imagine what it is for me - I've spent hours correcting this only to

have it

undone. I already work on this issue every day, 10-15 hours a day

usually,

and am fixing any problems I am aware of. But I have to be made aware

of

them. Please believe me.

Sandy from Alaska

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE

CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT

TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE

DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

[Guest guest]

> Kathy, This person didn't actually subscribe. There is no way to

> unsubscribe from my emails other than to contact me.

> Thanks for your sympathetic ear. Sandy

YK Sandy, that might be an idea though: open up groups under the names

you provided (i.e. once a week news update whatever) in groups and

let people sub to them. Then when you have something to send, send it

to those addys?

Then people *could* come and go freely...

Just a thought...

Fio, who has a delete key, and uses it liberally.

[Guest guest]

It's a great idea, but I cannot even get into at this point. Plus a lot of

the people on this list like to hear from me I think. Particularly for the

political action stuff - if I wait for everyone to think to look, the

opportunity might pass, and people who would have liked to know about it won't

have. (It was about 2 hours after I sent out the email re: the survey in the

Detroit News that it turned around from 29% to 66% or so. Plus at least half

the letters were generated by my email, I think.) I'd just as soon those people

get off the list - there is the website now for those who don't want to receive

any news. It's just that I keep removing them, and the computer keeps putting

them back - it's weird and I don't know why it is happening at this point. But

I think it is overloaded or something.

It wouldn't bother me if people were just nice about it. The last one today

must not have read my email explaining the problem. Or else was off the list

when I sent the email, and on the list afterwards, with no explanation.

Anyway, that's what the website is for. I guess my next project needs finding a

way to make sure the contacts don't keep disappearing and reverting to old

groups.

Sandy from Alaska

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED

HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED

AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO

BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION

WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE

AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR

HEALTH CARE PROVIDER.

Re: Please read this

> Kathy, This person didn't actually subscribe. There is no way to

> unsubscribe from my emails other than to contact me.

> Thanks for your sympathetic ear. Sandy

YK Sandy, that might be an idea though: open up groups under the names

you provided (i.e. once a week news update whatever) in groups and

let people sub to them. Then when you have something to send, send it

to those addys?

Then people *could* come and go freely...

Just a thought...

Fio, who has a delete key, and uses it liberally.

[Guest guest]

Sandy,

You do an amazing job here. I admire your commitment....dont let impatience

bother you.

:-D

Sue

[Guest guest]

Research - Oral Protease Inhibitor Trials Previous | Next

From: Barbara (SINDOLL) 9:10 am

ALL (1 of 1)

2109.1

This refers back to post 1891.1

HCV Protease Inhibitors: Vertex VX-950 clinical trial in 2003

At the large annual hepatitis/liver conference AASLD which was held

in November in Boston the first study results in HCV-infected

patients using an HCV protease inhibitor were presented by Boerhinger-

Ingleheim researchers. They reported encouraging results after

patients received the protease inhibitor BILN-2061. Here is a link to

NATAP's AASLD conference reports where you'll find 3 articles on the

2 studies conducted: http://www.natap.org/2002/AASLD/ndxAASLD.htm

Below is a press release from Vertex Pharma where they announce that

they look forward to starting a study with their protease inhibitor

in humans.

Vertex Pharmaceuticals Restructures Agreement with Eli Lilly; Vertex

to Lead Development of Novel Oral Hepatitis C Protease Inhibitor VX-

950

Thursday January 2, 4:05 pm ET -- VX-950 to Enter Clinical Trials in

2003 --CAMBRIDGE, Mass., Jan. 2 /CNW/ -- Vertex Pharmaceuticals

Incorporated announced today that it has restructured its agreement

with Eli Lilly and that Vertex will lead development and

commercialization of VX-950, a novel, oral hepatitis C viral protease

inhibitor. Vertex plans to begin clinical testing of VX-950 in the

second half of 2003. Preclinical studies of VX-950, begun in early

2002, are continuing in preparation for the commencement of Phase I

clinical trials. VX-950 is a small molecule protease inhibitor from a

new class of antiviral drugs that inhibit hepatitis C NS3-4A

protease, an enzyme considered essential for HCV viral replication.

The mutual decision to restructure the agreement is a result of a

reprioritization of Eli Lilly's research portfolio and Vertex's

desire to focus on specialty pharmaceutical markets and retain

greater downstream rights to its own compounds. In order to reflect

these strategic priorities, the companies have restructured their

agreement. Vertex has obtained the worldwide rights to compounds

identified during the collaboration. Eli Lilly will retain a

financial interest in VX-950 and other HCV protease compounds through

royalties on future net product sales.

Financial terms were not disclosed. " Vertex is enthusiastic about the

opportunity to drive forward development and commercialization of

this innovative compound. Obtaining worldwide rights to our HCV

protease inhibitor program is an important value creation step and

strengthens our antiviral and infectious disease portfolio. Our

clinical group is well-positioned to move VX-950 into the clinic and

capitalize on the value of our HCV protease inhibitor discovery

program, " said Boger, Ph.D., Chairman and CEO of Vertex. " Drugs

such as VX-950 could usher in a significant treatment advance and

provide a medical breakthrough for patients with HCV, " said

Alam, M.D., Vertex's Senior Vice President, Drug Evaluation and

Approval. " Recent clinical data from studies with another company's

HCV protease inhibitor compound have established initial proof-of-

concept for small molecule HCV protease inhibitors. VX-950 is a

distinct compound that has shown excellent in vitro potency, and high

levels of drug were achieved in both plasma and liver in animal

studies. We look forward to initiating clinical evaluation of VX-950

and to beginning to publish key data on Vertex's HCV protease

compounds in the second half of 2003. In addition, we also anticipate

that Vertex's ongoing HCV protease inhibitor discovery program will

produce an additional drug candidate in 2003 suitable for clinical

development. " Background on VX-950Vertex researchers solved the three-

dimensional atomic structure of HCV protease and reported the results

in the journal Cell in 1996. In 1997, Vertex began a collaboration

with Eli Lilly that has led to the discovery of HCV protease

inhibitors, and has pioneered novel chemistry and virology-based

approaches to design potent and selective compounds that block HCV

viral replication. Vertex and Lilly employed computational and

combinatorial chemistry techniques to create novel chemical

scaffolds, and Vertex developed a proprietary cell-based assay for

compound screening. VX-950 exhibits potent antiviral activity and

promising pharmacological properties in preclinical testing. During

Vertex's collaboration with Eli Lilly, Vertex has led efforts on HCV

protease inhibitor drug design, process development and pre-

commercial drug substance manufacturing work, and has taken the lead

in conducting ongoing toxicology studies.

The HCV protease inhibitor field has received renewed attention in

recent months, following presentation of the first clinical data on

another company's HCV protease inhibitor compound at the American

Association for the Study of Liver Disease (AASLD) meeting in

November 2002.Background on HCV InfectionHCV infection is a serious

disease that causes inflammation of the liver, which may lead to

fibrosis and cirrhosis, liver cancer, and ultimately, liver failure.

Chronic hepatitis C infection afflicts approximately 2.7 million

people in the U.S., many of whom are unaware of their infected

status. HCV may go undetected for up to 20 years following initial

infection. Worldwide, the disease strikes as many as 185 million

people. Each year, 8,000 to 10,000 people in the U.S. die from

complications of HCV.

Current treatments have been effective for only 40 to 60 percent of

chronically infected HCV patients and are associated with significant

side effects. At the present time, there are no direct antiviral

therapies available for the treatment of HCV infection.About

VertexVertex Pharmaceuticals Incorporated is a global biotechnology

company. Vertex seeks to discover, develop, and commercialize major

pharmaceutical products independently and with partners.

Chemogenomics, Vertex's proprietary, systematic, genomics-based

platform, is designed to accelerate the discovery of new drugs and to

expand intellectual property coverage of drug candidate compounds and

classes of related compounds. This approach, which targets gene

families, has formed the basis for several commercial collaborations

under which Vertex retains rights to downstream revenue. Vertex's

first approved product is Agenerase® (amprenavir), an HIV protease

inhibitor, which Vertex co-promotes with GlaxoKline. Vertex has

more than 12 drug candidates in clinical and preclinical development

to treat viral diseases, inflammation, cancer, autoimmune diseases,

neurological disorders and genetic disorders.This press release may

contain " forward-looking " statements, including statements that

Vertex's HCV protease research program will produce additional drug

candidates, that Vertex anticipates initiating clinical studies with

VX- 950 in the second half of 2003, and that HCV protease inhibitors

could provide a major clinical advance in treatment of HCV. While

Vertex's management uses its best efforts to be accurate in making

forward-looking statements, those statements are subject to risks and

uncertainties that could cause actual results to vary materially.

Those risks and uncertainties include, among other things, the risk

that further research may not be successful in identifying additional

drug candidates, that preclinical studies may not lead to the ...

[Message truncated]

View Full Message

Options Reply Rate

Subscribe

Software © 2002 Prospero Technologies LLC. All rights reserved.

Home | Upgrade your membership | Search | Create a Forum |

Advertising | About Delphi | Help | Tour

Copyright © 2003 Delphi Forums LLC. All rights reserved. Privacy

Policy.

E-Mail this MessageIgnore BarbaraPrint MessageBookmark PageReport

ViolationE-Mail this MessageStop Ignoring BarbaraPrint

MessageBookmark PageReport Violation